Update: Moving closer towards Abili-T data in SPMS
The Abili-T Phase IIb study evaluating Opexa’s Tcelna immunotherapy as a treatment for secondary progressive MS (SPMS) is nearing completion. The firm is fully funded to Phase IIb data, which are expected in early Q416 and, if positive, could sharply increase investor and stakeholder interest. Merck, the marketer of MS drug Rebif (interferon beta-1a), has an option to in-license Tcelna in MS. Our rNPV is $37.7m (vs $35.1m previously); after including $7.0m Q216 net cash, this gives an equity valuation of $44.8m.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.